All In Biotech

Drug Trial Radar · NCT02018757

Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCC

Clinical Application Study of Transarterial Chemoembolization Containing Arsenic Trioxide in the Treatment of Hepatocellular Carcinoma

Last checked: Nov 20, 2026Latest source record: May 28, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 250 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

250

Planned (sponsor's estimate)

Start

Jan 2014

Primary completion

Dec 2015

Sponsor

Lead sponsor
First Hospital of China Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sun Yat-sen University; Zhongda Hospital; Fudan University; Xijing Hospital
First posted
Dec 23, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine whether transarterial chemoembolization containing arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular carcinoma.

Conditions

  • Carcinoma, Hepatocellular

Interventions

  • TACE containing As2O3Drug

    transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol

  • TACE containing placeboDrug

    transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. time to progressionTime frame: From date of randomization until the date of first documented progression, up to 24 months

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Zhongshan Hospital Fudan University

    Shanghai, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • Xijing Hospital,Fourth Military Medical University

    Xi'an, Shaanxi, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.